Studying GLUT1 in immune cells of people with type 1 diabetes
Examines stored immune cell samples from people with type 1 diabetes to study GLUT1.
Plain-language title generated from the registry record
Registry title: Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- IRCCS San Raffaele Scientific InstituteMilan, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- IRCCS San Raffaele
- Trial code
- NCT07695727
- Record updated
- 14 July 2026
- Original description
Type 1 Diabetes is an autoimmune disease in which immune cells contribute to the destruction of insulin-producing pancreatic beta cells. This study investigates whether targeting glucose transporter 1 (GLUT1), a transporter involved in immune cell metabolism, may help modulate autoimmune responses associated with Type 1 Diabetes.Read full original descriptionShow less
Targeting GLUT1 to Control Autoimmunity in Type 1 Diabetes
Type 1 Diabetes is an autoimmune disease in which immune cells contribute to the destruction of insulin-producing pancreatic beta cells. This study investigates whether targeting glucose transporter 1 (GLUT1), a transporter involved in immune cell metabolism, may help modulate autoimmune responses associated with Type 1 Diabetes.
The study uses previously collected and biobanked peripheral blood mononuclear cells (PBMCs) from individuals with Type 1 Diabetes. No additional visits, blood draws, or study-specific procedures will be performed on human participants.
Inclusion: PBMC samples obtained from adult subjects aged 18 years or older at the time of sample collection; Documented diagnosis of Type 1 Diabetes; PBMC samples already collected and stored in the institutional Biobank of IRCCS Ospedale San Raffaele; PBMC samples obtained from subjects who had previously provided written informed consent for the collection, storage, and research use of biological material and associated data.
Exclusion: Presence of relevant concomitant diseases or clinical conditions that, in the Investigator's judgment and based on available records, may interfere with the interpretation of immunological analyses or with the study objectives; PBMC samples obtained from subjects younger than 18 years at the time of sample collection; Insufficient sample availability, inadequate sample quality, or missing essential sample-related information preventing use of the PBMC sample for the planned research activities.